...
首页> 外文期刊>Journal of Veterinary Pharmacology and Therapeutics >Pharmacokinetic-pharmacodynamic integration of orbifloxacin in rabbits after intravenous, subcutaneous and intramuscular administration.
【24h】

Pharmacokinetic-pharmacodynamic integration of orbifloxacin in rabbits after intravenous, subcutaneous and intramuscular administration.

机译:静脉,皮下和肌内给药后,奥比沙星在家兔体内的药代动力学-药效学整合。

获取原文
获取原文并翻译 | 示例

摘要

The single-dose disposition kinetics of orbifloxacin were determined in clinically normal rabbits (n = 6) after intravenous (i.v.), subcutaneous (s.c.) and intramuscular (i.m.) administration of 5 mg/kg bodyweight. Orbifloxacin concentrations were determined by high performance liquid chromatography with fluorescence detection. Minimal inhibitory concentrations (MICs) assay of orbifloxacin against 30 strains of Staphylococcus aureus from several European countries was performed in order to compute pharmacodynamic surrogate markers. The concentration-time data were analysed by compartmental and noncompartmental kinetic methods. Steady-state volume of distribution (V(ss)) and total body clearance (Cl) of orbifloxacin after i.v. administration were estimated to be 1.71 +/- 0.38 L/kg and 0.91 +/- 0.20 L/h.kg, respectively. Following s.c. and i.m. administration orbifloxacin achieved maximum plasma concentrations of 2.95 +/- 0.82 and 3.24 +/- 1.33 mg/L at 0.67 +/- 0.20 and 0.65 +/- 0.12 h, respectively. The absolute bio-availabilities after s.c. and i.m. routes were 110.67 +/- 11.02% and 109.87 +/- 8.36%, respectively. Orbifloxacin showed a favourable pharmacokinetic profile in rabbits. However, on account of the low AUC/MIC and C(max)/MIC indices obtained, its use by i.m. and s.c. routes against the S. aureus strains assayed in this study cannot be recommended given the risk of selection of resistant populations.
机译:在静脉内(i.v.),皮下(s.c.)和肌内(i.m.)施用5 mg / kg体重后,在临床正常的兔子(n = 6)中确定了奥比沙星的单剂量处置动力学。奥比沙星浓度通过高效液相色谱-荧光检测法测定。为了计算药效学替代标记,对来自几个欧洲国家的30株金黄色葡萄球菌进行了奥比沙星的最小抑菌浓度(MICs)测定。通过隔室和非隔室动力学方法分析浓度-时间数据。静脉输注奥比沙星的稳态分布体积(V(ss))和全身清除率(Cl)。估计施用量分别为1.71 +/- 0.38 L / kg和0.91 +/- 0.20 L / h.kg。跟随s.c.和我服用奥比沙星在0.67 +/- 0.20和0.65 +/- 0.12 h时分别达到2.95 +/- 0.82和3.24 +/- 1.33 mg / L的最大血浆浓度。 s.c.之后的绝对生物利用度和我路线分别为110.67 +/- 11.02%和109.87 +/- 8.36%。奥比沙星在兔中显示出良好的药代动力学特征。但是,由于获得的AUC / MIC和C(max)/ MIC指数较低,因此i.m.使用。和s.c.考虑到选择抗性种群的风险,因此不建议针对本研究中测定的针对金黄色葡萄球菌菌株的途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号